Anti-Mouse NKG2D/CD314 Antibody (CX5)
Based on 1 Customer Validation
Anti-Mouse NKG2D/CD314 Antibody (CX5) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse NKG2D/CD314. Anti-Mouse NKG2D/CD314 Antibody (CX5) reduces cytotoxicity of natural killer cells. Anti-Mouse NKG2D/CD314 Antibody (CX5) can be used for the researches of cancer, infection, inflammation, immunology and metabolic disease, such as colitis and diabetes.
For research use only. We do not sell to patients.
- Purity: 95.47%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Rat IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
NKG2D/CD314
In Vitro
Anti-Mouse NKG2D/CD314 Antibody (CX5) (10 μg/mL) reduces lysed leukemia cells by natural killer cells[2].
Anti-Mouse NKG2D/CD314 Antibody (CX5) (10 μg/mL, 30 mins) significantly decreases the cytolytic activity of natural killer cells and abolishes the enriched environment–induced enhancement of natural killer-cell cytotoxicity to YAC-1 and Panc02 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Anti-Mouse NKG2D/CD314 Antibody (CX5) (100 μg, i.v., 1 day before transplant and day 0) reduces elimination of leukemia cells by natural killer cells in MLL/ENL-HPCs transplanted mice models[2].
Anti-Mouse NKG2D/CD314 Antibody (CX5) (200 μg, i.p., twice a week from 2 to 4 week) attenuates colitis in SCID mice[3].
Anti-Mouse NKG2D/CD314 Antibody (CX5) (200 μg, i.p., every 3 days beginning from 3 days before tumor cell implantation) promotes tumor growth in Panc02 tumor mice models[4].
Anti-Mouse NKG2D/CD314 Antibody (CX5) (50 μg, i.p., at days 6-10 after LCMV inoculation) prevents diabetes companied with GAD65-specific CD4+ T cells in lymphocytic choriomeningitis virus (LMCV)-induced diabetic mice models[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Islet transplantation diabetic mice models[1]
-
Dosage:8 mg/kg at days 0-5 and three times per week
-
Administration:Intraperitoneally injection, companied with CTLA-4 Ig
-
Result:Prolonged graft survival and showed euglycemia.
Decreased NKG2D+ cells and proliferation of CD8+ T cells.
-
Animal Model:Colitis mice models[3]
-
Dosage:200 μg
-
Administration:Intraperitoneally injection, twice a week from 2 to 4 week
-
Result:Showed no CD4+NKG2D+ cells and lower increase in the white blood cell.
Reduced weight:length ratio of colon and colonic wall thickness.
-
Animal Model:Panc02 tumor mice models[4]
-
Dosage:200 μg
-
Administration:Intraperitoneally injection, every 3 days beginning from 3 days before tumor cell implantation
-
Result:Promoted tumor growth.
Abrogated the enriched environment-induced inhibitory effect on tumor growth.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vivo NKG2D blockade; in vitro NKG2D blockade; Flow Cytometry
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse NKG2D/CD314 Antibody (CX5)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Pawlick R, et al. The combination of anti-NKG2D and CTLA-4 Ig therapy prolongs islet allograft survival in a murine model. Am J Transplant. 2014 Oct;14(10):2367-74. [Content Brief]
[2]. Nakata J, et al. In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity. Leukemia. 2014 Jun;28(6):1316-25. [Content Brief]
[3]. Kjellev S, et al. Inhibition of NKG2D receptor function by antibody therapy attenuates transfer-induced colitis in SCID mice. Eur J Immunol. 2007 May;37(5):1397-406. [Content Brief]
[4]. Song Y, et al. Enriching the Housing Environment for Mice Enhances Their NK Cell Antitumor Immunity via Sympathetic Nerve-Dependent Regulation of NKG2D and CCR5. Cancer Res. 2017 Apr 1;77(7):1611-1622. [Content Brief]
[5]. Van Belle TL, et al. NKG2D blockade facilitates diabetes prevention by antigen-specific Tregs in a virus-induced model of diabetes. J Autoimmun. 2013 Feb;40:66-73. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse NKG2D/CD314 Antibody (CX5) Related Classifications
HY-P990178 Related Classifications
Powered by Bioz